What caused the decline in KURN.SW stock today?

KURN.SW stock fell **2.62%** amid profit-taking and weak short-term technicals. Volume of **133,403** shares and a price drop below the 50-day average increased selling pressure. No single public news item explained the move; market sentiment toward small-cap biotech weighed on the stock.

What is Meyka AI's view on KURN.SW stock?

Meyka AI gives KURN.SW a **72.19** score (Grade **B+**, Suggestion **BUY**). The rating balances growth forecasts, sector comparison, and key metrics. This grade is informational and not personalised investment advice.

How does the Meyka AI forecast compare to the current price?

Meyka AI's forecast model projects a yearly target of **CHF36.56**, implying **+44.65%** upside from **CHF25.28**. Shorter-term monthly and quarterly projections suggest modest downside. Forecasts are model-based and not guarantees.

What key dates should investors watch for KURN.SW stock?

The next important date is the earnings announcement on **2026-03-10**. Clinical readouts and regulatory updates for KUR-111, KUR-113 and Neuroseal will also be market catalysts in the coming months.

CH Stocks

KURN.SW stock down 2.62% to CHF25.28 on SIX: top losers signal

ByHuzaifa Zahoor February 12, 2026February 12, 2026

KURN.SW stock closed lower after a -2.62% drop to CHF25.28 on the SIX market as investors sold into weakness. Volume reached 133,403 shares versus an average of 147,077. Today’s move reinforced a short-term downtrend that left the share price below the 50-day average of CHF27.60. We review why Kuros Biosciences AG (KURN.SW) appears among the top losers and what catalysts could matter next for Switzerland’s biotech investor community.